Banyu Pharmaceutical Co. Ltd

Takashi Hashihayata

Mikako Kawamura

Yoshikazu Iwasawa

Morihiro Mitsuya

Yoshiyuki Sato

Tadashi Shimamura

Nobuhiko Kawanishi

Takeshi Sagara

Hiroshi Hirai

Takashi Mita

Fuyuki Yamamoto

Satoshi Sunami

Sachie Arai

Tetsuya Sugimoto

Hideki Kurihara

Hideya Komatani

Kaori Kamijo

The present invention relates to a compound represented by Formula [I]: or a pharmaceutically acceptable salt or ester thereof, wherein Rand R, which may be the same or different, are each a hydrogen atom, a lower alkyl group, a cycloalkyl group, or the like; Rand R, which may be the same or different, are each a hydrogen atom, a lower alkyl group, NRR, a phenyl group, a lower alkyl group substituted with a phenyl group, a 4-to 7-membered aliphatic heterocyclic group, a lower alkyl group substituted with a 4- to 7-membered aliphatic heterocyclic group, a 5-or 6-membered aromatic heterocyclic group, a lower alkyl group substituted with a 5-or 6-membered aromatic heterocyclic group, or the like; and Ris a hydrogen atom, a cyano group, a halogen atom, or a lower alkyl group.

Aminopyrimidine derivatives as PLK1 inhibitors

The present invention relates to a compound represented by Formula [I] or a pharmaceutically acceptable salt or ester thereof: wherein:

Substituted imidazole derivative

The present invention relates to a compound represented by Formula [I]: wherein

Selective inhibitors against Cdk4 and Cdk6 having aminothiazole skeleton

Growing community of inventors

Tsukuba, Japan

Takashi Hashihayata